Peroxisomal Dysfunction in Age-Related Diseases

Trends in Endocrinology and Metabolism

Volumn 28, Issue 4, 2017, Pages 297-308

  Cipolla, Cynthia M ^a   Lodhi, Irfan J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

aging; neurodegeneration; peroxisome; pexophagy; reactive oxygen species

Indexed keywords

ACYL COENZYME A; ETHER LIPID; PLASMALOGEN; REACTIVE OXYGEN METABOLITE;

AGING; AUTOPHAGY; CANCER CELL; CELL METABOLISM; DEGENERATIVE DISEASE; DIABETES MELLITUS; DISEASE COURSE; DISORDERS OF PEROXISOMAL FUNCTIONS; FATTY ACID OXIDATION; GENETIC DISORDER; HUMAN; LIPID METABOLISM; LIPOGENESIS; LIPOTOXICITY; MALIGNANT NEOPLASM; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PEROXISOME; PEXOPHAGY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; TUMOR MICROENVIRONMENT; ANIMAL; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGING; ANIMALS; HUMANS; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; PEROXISOMES; REACTIVE OXYGEN SPECIES;

EID: 85008470440     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2016.12.003     Document Type: Review

References (88)

1. 1 Schrader, M., et al. Peroxisome interactions and cross-talk with other subcellular compartments in animal cells. Subcell. Biochem. 69 (2013), 1–22.
2. 2 Lodhi, I.J., Semenkovich, C.F., Peroxisomes: a nexus for lipid metabolism and cellular signaling. Cell Metab. 19 (2014), 380–392.
3. 3 Braverman, N.E., et al. Peroxisome biogenesis disorders in the Zellweger spectrum: an overview of current diagnosis, clinical manifestations, and treatment guidelines. Mol. Genet. Metab. 117 (2016), 313–321.
4. 4 Waterham, H.R., Ebberink, M.S., Genetics and molecular basis of human peroxisome biogenesis disorders. Biochim. Biophys. Acta 1822 (2012), 1430–1441.
5. 5 Fransen, M., et al. Aging, age-related diseases and peroxisomes. del Rio, L.A., (eds.) Peroxisomes and Their Key Role in Cellular Signaling and Metabolism, 2013, Springer, 45–65.
6. 6 Lousa, C.D.M., et al. Intrinsic acyl-CoA thioesterase activity of a peroxisomal ATP binding cassette transporter is required for transport and metabolism of fatty acids. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 1279–1284.
7. 7 Schrader, M., et al. Peroxisome-mitochondria interplay and disease. J. Inherit. Metab. Dis. 38 (2015), 681–702.
8. 8 Noland, R.C., et al. Peroxisomal-mitochondrial oxidation in a rodent model of obesity-associated insulin resistance. Am. J. Physiol. Endocrinol. Metab. 293 (2007), E986–E1001.
9. 9 Singh, I., et al. Lignoceric acid is oxidized in the peroxisome: implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy. Proc. Natl. Acad. Sci. U. S. A. 81 (1984), 4203–4207.
10. 10 Reddy, J.K., Hashimoto, T., Peroxisomal β-oxidation and peroxisome proliferator-activated receptor α: an adaptive metabolic system. Annu. Rev. Nutr. 21 (2001), 193–230.
11. 11 Wanders, R.J.A., Peroxisomes and their key role in cellular signaling and metabolism. Subcell. Biochem. 69 (2013), 23–44.
12. 12 Wanders, R.J.A., Metabolic functions of peroxisomes in health and disease. Biochimie 98 (2014), 36–44.
13. 13 Hajra, A.K., Das, A.K., Lipid biosynthesis in peroxisomes. Ann. N. Y. Acad. Sci. 804 (1996), 129–141.
14. 14 Lodhi, I.J., et al. Inhibiting adipose tissue lipogenesis reprograms thermogenesis and PPARγ activation to decrease diet-induced obesity. Cell Metab. 16 (2012), 189–201.
15. 15 Lodhi, I.J., et al. Peroxisomal lipid synthesis regulates inflammation by sustaining neutrophil membrane phospholipid composition and viability. Cell Metab. 21 (2015), 51–64.
16. 16 Rodemer, C., et al. Inactivation of ether lipid biosynthesis causes male infertility, defects in eye development and optic nerve hypoplasia in mice. Hum. Mol. Genet. 12 (2003), 1881–1895.
17. 17 Amaral, A., et al. Human sperm tail proteome suggests new endogenous metabolic pathways. Mol. Cell. Proteomics 12 (2013), 330–342.
18. 18 Miyazaki, C., et al. Altered phospholipid molecular species and glycolipid composition in brain, liver and fibroblasts of Zellweger syndrome. Neurosci. Lett. 552 (2013), 71–75.
19. 19 Facciotti, F., et al. Peroxisome-derived lipids are self antigens that stimulate invariant natural killer T cells in the thymus. Nat. Immunol. 13 (2012), 474–480.
20. 20 Ferdinandusse, S., et al. Bile acids: the role of peroxisomes. J. Lipid Res. 50 (2009), 2139–2147.
21. 21 Kovacs, W.J., et al. Localization of the pre-squalene segment of the isoprenoid biosynthetic pathway in mammalian peroxisomes. Histochem. Cell Biol. 127 (2007), 273–290.
22. 22 Wanders, R.J., Waterham, H.R., Biochemistry of mammalian peroxisomes revisited. Annu. Rev. Biochem. 75 (2006), 295–332.
23. 23 Chu, B-B., et al. Cholesterol transport through lysosome-peroxisome membrane contacts. Cell 161 (2015), 291–306.
24. 24 Legakis, J.E., et al. Peroxisome senescence in human fibroblasts. Mol. Biol. Cell 13 (2002), 4243–4255.
25. 25 Boveris, A., et al. The cellular production of hydrogen peroxide. Biochem. J. 128 (1972), 617–630.
26. 26 Fransen, M., et al. Role of peroxisomes in ROS/RNS-metabolism: implications for human disease. Biochim. Biophys. Acta 1822 (2012), 1363–1373.
27. 27 Antonenkov, V.D., et al. Peroxisomes are oxidative organelles. Antioxid. Redox Signal. 13 (2010), 525–537.
28. 28 Nunnari, J., Suomalainen, A., Mitochondria: in sickness and in health. Cell 148 (2012), 1145–1159.
29. 29 Terlecky, S.R., et al. Peroxisomes, oxidative stress, and inflammation. World J. Biol. Chem. 3 (2012), 93–97.
30. 30 Ivashchenko, O., et al. Intraperoxisomal redox balance in mammalian cells: oxidative stress and interorganellar cross-talk. Mol. Biol. Cell 22 (2011), 1440–1451.
31. 31 Hwang, I., et al. Catalase deficiency accelerates diabetic renal injury through peroxisomal dysfunction. Diabetes 61 (2012), 728–738.
32. 32 Narayan, V., et al. Deep proteome analysis identifies age-related processes in C. elegans. Cell Syst. 3 (2016), 144–159.
33. 33 Dodt, G., Gould, S.J., Multiple PEX genes are required for proper subcellular distribution and stability of Pex5p, the PTS1 receptor: evidence that PTS1 protein import is mediated by a cycling receptor. J. Cell Biol. 135 (1996), 1763–1774.
34. 34 Liu, X., et al. Recent advances in peroxisomal matrix protein import. Curr. Opin. Cell Biol. 24 (2012), 484–489.
35. 35 Freitas, M.O., et al. PEX5 protein binds monomeric catalase blocking its tetramerization and releases it upon binding the n-terminal domain of PEX14. J. Biol. Chem. 286 (2011), 40509–40519.
36. 36 Ma, C., et al. Redox-regulated cargo binding and release by the peroxisomal targeting signal receptor. Pex5. J. Biol. Chem. 288 (2013), 27220–27231.
37. 37 Apanasets, O., et al. PEX5, the shuttling import receptor for peroxisomal matrix proteins, is a redox-sensitive protein: PTS1 protein import and oxidative stress. Traffic 15 (2014), 94–103.
38. 38 Huybrechts, S.J., et al. Peroxisome dynamics in cultured mammalian cells. Traffic 10 (2009), 1722–1733.
39. 39 Manjithaya, R., et al. Molecular mechanism and physiological role of pexophagy. FEBS Lett. 584 (2010), 1367–1373.
40. 40 Zientara-Rytter, K., Subramani, S., Autophagic degradation of peroxisomes in mammals. Biochem. Soc. Trans. 44 (2016), 431–440.
41. 41 Rogov, V., et al. Interactions between autophagy receptors and ubiquitin-like proteins form the molecular basis for selective autophagy. Mol. Cell 53 (2014), 167–178.
42. 42 Oku, M., Sakai, Y., Pexophagy in yeasts. Biochim. Biophys. Acta 1863 (2016), 992–998.
43. 43 Nordgren, M., et al. Export-deficient monoubiquitinated PEX5 triggers peroxisome removal in SV40 large T antigen-transformed mouse embryonic fibroblasts. Autophagy 11 (2015), 1326–1340.
44. 44 Zhang, J., et al. ATM functions at the peroxisome to induce pexophagy in response to ROS. Nat. Cell Biol. 17 (2015), 1259–1269.
45. 45 Zhang, J., et al. A tuberous sclerosis complex signalling node at the peroxisome regulates mTORC1 and autophagy in response to ROS. Nat. Cell Biol. 15 (2013), 1186–1196.
46. 46 Walter, K.M., et al. Hif-2α promotes degradation of mammalian peroxisomes by selective autophagy. Cell Metab. 20 (2014), 882–897.
47. 47 Sargent, G., et al. PEX2 is the E3 ubiquitin ligase required for pexophagy during starvation. J. Cell Biol. 214 (2016), 677–690.
48. 48 Ashcroft, F.M., Rorsman, P., Diabetes mellitus and the β cell: the last ten years. Cell 148 (2012), 1160–1171.
49. 49 Hauck, A.K., Bernlohr, D.A., Oxidative stress and lipotoxicity. J. Lipid Res. 57 (2016), 1976–1986.
50. 50 Supale, S., et al. Mitochondrial dysfunction in pancreatic β cells. Trends Endocrinol. Metab. 23 (2012), 477–487.
51. 51 Elsner, M., et al. Peroxisome-generated hydrogen peroxide as important mediator of lipotoxicity in insulin-producing cells. Diabetes 60 (2011), 200–208.
52. 52 Kim, D., et al. Peroxisomal dysfunction is associated with up-regulation of apoptotic cell death via miR-223 induction in knee osteoarthritis patients with type 2 diabetes mellitus. Bone 64 (2014), 124–131.
53. 53 Vasko, R., et al. Endothelial peroxisomal dysfunction and impaired pexophagy promotes oxidative damage in lipopolysaccharide-induced acute kidney injury. Antioxid. Redox Signal. 19 (2013), 211–230.
54. 54 Giordano, C.R., et al. Catalase therapy corrects oxidative stress-induced pathophysiology in incipient diabetic retinopathy. Investig. Opthalmology Vis. Sci., 56, 2015, 3095.
55. 55 Kou, J., et al. Peroxisomal alterations in Alzheimer's disease. Acta Neuropathol. (Berl.) 122 (2011), 271–283.
56. 56 Shi, Y., et al. Elevation of cortical C26:0 due to the decline of peroxisomal β-oxidation potentiates amyloid β generation and spatial memory deficits via oxidative stress in diabetic rats. Neuroscience 315 (2016), 125–135.
57. 57 Giordano, C.R., et al. Amyloid-beta neuroprotection mediated by a targeted antioxidant. Sci. Rep., 4, 2014, 4983.
58. 58 Puchkov, D., Haucke, V., Greasing the synaptic vesicle cycle by membrane lipids. Trends Cell Biol. 23 (2013), 493–503.
59. 59 Brodde, A., et al. Impaired neurotransmission in ether lipid-deficient nerve terminals. Hum. Mol. Genet. 21 (2012), 2713–2724.
60. 60 Bennett, S.A.L., et al. Using neurolipidomics to identify phospholipid mediators of synaptic (dys)function in Alzheimer's disease. Front. Physiol., 4, 2013, 168.
61. 61 Fabelo, N., et al. Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease. Mol. Med., 17, 2011, 1107.
62. 62 Miville-Godbout, E., et al. Plasmalogen augmentation reverses striatal dopamine loss in MPTP mice. PLoS One, 11, 2016, e0151020.
63. 63 Wang, S., et al. A peroxisome biogenesis deficiency prevents the binding of alpha-synuclein to lipid droplets in lipid-loaded yeast. Biochem. Biophys. Res. Commun. 438 (2013), 452–456.
64. 64 Benjamin, D.I., et al. Global profiling strategies for mapping dysregulated metabolic pathways in cancer. Cell Metab. 16 (2012), 565–577.
65. 65 Snyder, F., Wood, R., Alkyl and alk-1-enyl ethers of glycerol in lipids from normal and neoplastic human tissues. Cancer Res. 29 (1969), 251–257.
66. 66 Saito, K., et al. Lipidomic signatures and associated transcriptomic profiles of clear cell renal cell carcinoma. Sci. Rep., 6, 2016, 28932.
67. 67 Phuyal, S., et al. The ether lipid precursor hexadecylglycerol stimulates the release and changes the composition of exosomes derived from PC-3 cells. J. Biol. Chem. 290 (2015), 4225–4237.
68. 68 Uyama, T., et al. Regulation of peroxisomal lipid metabolism by catalytic activity of tumor suppressor H-rev107. J. Biol. Chem. 287 (2012), 2706–2718.
69. 69 Uyama, T., et al. Interaction of phospholipase A/acyltransferase-3 with Pex19p: a possible involvement in the down-regulation of peroxisomes. J. Biol. Chem. 290 (2015), 17520–17534.
70. 70 Jones, J.M., et al. PEX19 is a predominantly cytosolic chaperone and import receptor for class 1 peroxisomal membrane proteins. J. Cell Biol. 164 (2004), 57–67.
71. 71 Benjamin, D.I., et al. Ether lipid generating enzyme AGPS alters the balance of structural and signaling lipids to fuel cancer pathogenicity. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 14912–14917.
72. 72 Zhu, Y., et al. Role and mechanism of the alkylglycerone phosphate synthase in suppressing the invasion potential of human glioma and hepatic carcinoma cells in vitro. Oncol. Rep. 32 (2014), 431–436.
73. 73 Piano, V., et al. Discovery of inhibitors for the ether lipid-generating enzyme AGPS as anti-cancer agents. ACS Chem. Biol. 10 (2015), 2589–2597.
74. 74 Rubin, M.A., et al. α-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287 (2002), 1662–1670.
75. 75 Lloyd, M.D., et al. α-Methylacyl-CoA racemase (AMACR): metabolic enzyme, drug metabolizer and cancer marker P504S. Prog. Lipid Res. 52 (2013), 220–230.
76. 76 Li, C-F., et al. AMACR amplification in myxofibrosarcomas: a mechanism of overexpression that promotes cell proliferation with therapeutic relevance. Clin. Cancer Res. 20 (2014), 6141–6152.
77. 77 Liu, Y., Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis. 9 (2006), 230–234.
78. 78 Vander Heiden, M.G., et al. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324 (2009), 1029–1033.
79. 79 Liberti, M.V., Locasale, J.W., The Warburg effect: how does it benefit cancer cells?. Trends Biochem. Sci. 41 (2016), 211–218.
80. 80 Freitag, J., et al. Cryptic peroxisomal targeting via alternative splicing and stop codon read-through in fungi. Nature 485 (2012), 522–525.
81. 81 Schueren, F., et al. Peroxisomal lactate dehydrogenase is generated by translational readthrough in mammals. Elife, 3, 2014, e03640.
82. 82 Stiebler, A.C., et al. Ribosomal readthrough at a short UGA stop codon context triggers dual localization of metabolic enzymes in fungi and animals. PLoS Genet., 10, 2014, e1004685.
83. 83 McClelland, G.B., et al. Peroxisomal membrane monocarboxylate transporters: evidence for a redox shuttle system?. Biochem. Biophys. Res. Commun. 304 (2003), 130–135.
84. 84 Doherty, J.R., Cleveland, J.L., Targeting lactate metabolism for cancer therapeutics. J. Clin. Invest. 123 (2013), 3685–3692.
85. 85 Valença, I., et al. Localization of MCT2 at peroxisomes is associated with malignant transformation in prostate cancer. J. Cell. Mol. Med. 19 (2015), 723–733.
86. 86 Pertega-Gomes, N., et al. Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer. Oncotarget 6 (2015), 21675–21684.
87. 87 DeLoache, W.C., et al. Towards repurposing the yeast peroxisome for compartmentalizing heterologous metabolic pathways. Nat. Commun., 7, 2016, 11152.
88. 88 Zhou, Y.J., et al. Harnessing yeast peroxisomes for biosynthesis of fatty-acid-derived biofuels and chemicals with relieved side-pathway competition. J. Am. Chem. Soc. 138 (2016), 15368–15377.